What To Know
- “Joe’s decades of strategy and market development experience have been critical in expanding our footprint and technologies in home dialysis and critical care since he joined us as part of the NxStage merger in 2019,”.
- “We have an incredible opportunity as the market leader to work together to ensure we’re providing the highest quality care and renal products to the patients we are privileged to serve.
Fresenius Medical Care North America (FMCNA), the nation’s leading provider of kidney care products, announced today that Joseph (Joe) Turk has been named President for the company’s Renal Therapies Group.
In his new role, Joe Turk will be responsible for overseeing Renal Products and Pharmaceutical operations, including sales, clinical support, product marketing and management, customer and technical services, and regulatory affairs.
Having previously served as FMCNA’s President of Home and Critical Care Therapies, these expanded responsibilities align the company’s products teams into one organization – with a focus on efficiently and effectively delivering new technologies to support people living with kidney disease.
“Joe’s decades of strategy and market development experience have been critical in expanding our footprint and technologies in home dialysis and critical care since he joined us as part of the NxStage merger in 2019,” said Bill Valle, Chief Executive Officer, FMCNA. “Joe’s leadership will be instrumental as we focus on better leveraging best practices across divisions for the benefit of our customers, partners, field teams, and most importantly our patients.”
Turk succeeds Mark Costanzo, who recently retired as President of FMCNA’s Renal Therapies Group.
“I am thrilled to bring our exceptional teams together at this important time,” said Turk. “We have an incredible opportunity as the market leader to work together to ensure we’re providing the highest quality care and renal products to the patients we are privileged to serve.”
